Business Wire

FL-KINAXIS

Share
Introducing Maestro: The First AI-Infused Supply Chain Orchestration Platform from Kinaxis

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today introduced the Kinaxis Maestro™ platform, the only AI-infused supply chain orchestration platform with a powerful combination of proprietary computational technologies and techniques that provides full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. An evolution of the company’s flagship platform, RapidResponse, Maestro incorporates new, modern AI technologies to help teams move faster and smarter to master the complexities of today’s modern supply chains.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618998841/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kinaxis announced its AI-infused orchestration platform, Maestro, at global supply chain conference Kinexions in Miami, FL. (Graphic: Business Wire)

The Maestro platform comprises three layers: a supply chain data fabric connecting internal and external data sources into a single source of truth, an always-on intelligence engine that delivers real-time insights, predictions and adaptive solutions, and a seamless user interface, enabling business leaders to make faster and more valuable decisions than ever before, from anywhere and from any device. For example, in response to skyrocketing demand of a new EV following a high-profile celebrity endorsement, an automaker concerned about component shortages might ask ‘How do I prevent a stockout?’. Without missing a beat, Maestro’s generative AI-powered intelligent assistant will provide guidance based on supply chain best practices to ensure disruptions are absorbed and managed in real-time.

"It’s a challenging time to be a business leader in supply chain. Managing the complexities of global and regional supply chains, balancing agility, cost reduction, and sustainability, and handling a steady stream of geopolitical, economic, and environmental disruptions amid a data explosion,” said Andrew Bell, chief product officer at Kinaxis. “Yet, with the right technologies, there's unprecedented potential to resolve this complexity and master uncertainty. Maestro provides total supply chain transparency, aligns advanced technology with specific challenges, and integrates diverse data—from social media sentiment to government regulations—bringing clarity to chaos so business leaders can sleep soundly at night."

National Instruments took part in the beta phase of Maestro’s generative AI capabilities and Ed Scott, chief program manager said, “From the moment our team deployed Maestro’s intelligent assistant, it was clear it would be a gamechanger. We’ve been able to significantly cut down on the amount of time it takes for users to maximize the value of the platform and we are eager to build on these initial successes as Kinaxis continues to roll out the full breadth of its AI capabilities.”

What makes Maestro different:

  • Seamless synchronization. Unmatched agilityGain a comprehensive, always-on digital view of your supply chain, ensuring continuous synchronization of data, people, and processes for unmatched agility.
  • Be ready. Whatever happensPredict future scenarios with smart modeling and make informed decisions quickly to confidently navigate uncertainties and drive success.
  • Strike the perfect balance of accuracy, efficiency, and speed – Fuse machine learning, heuristics and optimization for unparalleled problem-solving, keeping your supply chain at the cutting edge.
  • Take your productivity to the next level – Automate routine tasks with AI and predictive algorithms, allowing you to focus on strategic priorities and boost productivity.
  • Empower your people to do more with more – Empower your teams with an intuitive tool that simplifies complex tasks and enhances efficiency, enabling greater satisfaction and achievement.
  • No data wrangling required – Achieve faster time-to-value by easily ingesting data from various sources without the need for schema definition; just drag, drop, and go.

Global market intelligence firm IDC previewed Maestro prior to launch and Eric Thompson, IDC Worldwide Supply Chain Planning Research Director, noted, “IDC has been discussing end-to-end supply chain integration, and Kinaxis is making moves forward with Maestro. The platform’s progress in combining end-to-end concurrency with smart, user-friendly AI, is a promising step in supply chain orchestration.”

From building the first in-memory material requirements planning (MRP) engine in the 1980s to adopting a SaaS model years before its peers and launching the first cloud-friendly planning platform in the 2000s, Kinaxis has been at the forefront of every major technological innovation within the supply chain industry for the past four decades. The company has consistently prioritized designing products to meet the evolving needs of its customers, focusing on pillars of connectivity, intelligence, adaptability, and user-friendliness. In the previous five years alone, the company’s patent portfolio has grown by more than 500%, with over half of those patents awarded for AI and ML-based innovations.

Celebrating its 40th anniversary in 2024, Kinaxis helps companies that supply the agricultural industry with 40% of the world’s tractors, that keep more than 110 billion teeth clean each year, and that ensure more than 35 million pets are fed nutritious meals each year.

About Kinaxis

Kinaxis is a global leader in modern supply chain orchestration. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to manage their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618998841/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye